Magnesium Treatment in Hypoparathyroidism

Effect of Magnesium Treatment on Plasma Calcium in Hypoparathyroid Patients

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00824226

Enrollment

Registered

2009-01-16

Start date

2009-01-31

Completion date

2011-08-31

Last updated

2011-08-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypoparathyroidism

Keywords

primary hypoparathyroidism, secondary hypoparathyroidism, magnesium

Brief summary

Study hypothesis: supplementary magnesium may influence the blood calcium level in treated hypoparathyroid patients. Patients will be treated with supplementary magnesium (350 mg/day) for 3 weeks. Calcium and other relevant blood parameters will be measured before the treatment, at the end of treatment and 2 weeks after stopping treatment.

Interventions

DIETARY_SUPPLEMENTmagnesium

magnesium 350 mg tablets once a day for 3 weeks

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* primary or secondary hypoparathyroidism * treatment with calcium plus vitamin D analogue * ionized calcium 1,0-1,29 mmol/L * magnesium level 0,7-1,05 mmol/L * TSH 0.1- 10 imU/L

Exclusion criteria

* any other disease known to influence plasma Ca level * pregnancy * creatinine \> 150 microM/L * patient has used supplementary magnesium within 2 previous months

Design outcomes

Primary

Measure	Time frame
Calcium level at the end of magnesium treatment compared to pretreatment level	3 weeks

Secondary

Measure	Time frame
Calcium level after stopping treatment compared to the level at the end of magnesium treatment	2 weeks

Countries

Estonia

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026